No more squinting at menus? Visus Therapeutics nabs $36M for presbyopia-correcting eye drop
Visus Therapeutics is off to a bit of a late start in the race for a therapeutic alternative to reading glasses. But with an added $36 million in the bank, CEO Ben Bergo is eyeing a quick Phase II launch for the company’s double-agent eye drops.
Bergo co-founded Visus back in 2019, after securing the patents to the company’s lead candidate Brimochol from antiviral pioneer Herb Kaufman. The miotic-based eye drop for presbyopia is a combination of two FDA-approved pharmaceuticals: carbachol (marketed as Miostat) and brimonidine tartrate.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.